INDIANA HEALTH COVERAGE PROGRAMS (IHCP) ADULT (≥18 YEARS OF AGE) GROWTH HORMONE PRIOR AUTHORIZATION REQUEST FORM



Today's Date

MDwise Fax to: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department 10181 Scripps Gateway Court, San Diego, CA 92131 Phone: (808) 788-2949



Note: This form must be completed by the p	rescribing	provider.		
All sections must be	complete	d or the request v	will be returned	
Patient's Medicaid #		Date of Birth / / / / / / / / / / / / / / / / / / /		
Patient's Name	Prescriber's Name			
Prescriber's IN License #	Specialty			
Prescriber's NPI#	Prescriber's Signature			
Return Fax #	- Return Phone			
Check box if requesting retro-active PA		Date(s) of service requested for retro-active eligibility (if applicable):		
Note: Submit PA requests for retroactive claims (dates eligibility timelines) with dates of service prior to 30 ca service 30 calendar days or less and going forward).				
Requested Medication and Strength	Do	sage	Treatment Duration	
SOMATROPIN AGENTS – Initial Authorization	on			
Please select one of the following: Member is transitioning from pediatric g *Must meet all of the following* Member has reached adult heighter Member stopped growth hormore for continued therapy Prescriber has determined that adulthood and would receive cles Please select one of the following: Request is for a preferred agent Request is for a non-preferred at List indication:	growth horm ght one therapy member w linical benefit agent with a	for at least 1 mon ill experience grow fit from continued of a product-specific i	growth hormone therapy	

	Member has a diagno	osis of adult growth he	ormone deficiency		
	*The following docu	ımentation will be re	equired for diagnosi	_	none deficiency"
	 Biochemical Please select one of 		plicable testing suppo	orting the diagnosis	
		r a preferred agent			
	·		ent with a product-spe		
			an professed agent ov		based on the following
	medical justif		on-preferred agent ov	er preferred agent i	based off the following
	Diagnosis of HIV-ass	ociated wasting or ca	chexia (Serostim only	/)	
	_	_	equired for diagnosi	*	ted wasting or
				XA (dual energy X	-ray absorptiometry) or
	`	ric impedance analys on of involuntary weig	sis) ght loss of >10% of ba	aseline total body w	reight OR body cell
		for initial approval		•	,
	Member's current All	DS/HIV anti-retroviral	regimen:		
	Member has tried an	d failed one of the fol	lowing (include trial da	ate dose frequenc	v duration reason
			☐ Anabolic Steroids	·	-
			•		to ensure there are no
expan	ding intracranial lesion	s or tumors prior to in	nitiating growth hormo	ne therapy \(\square\) Yes	s 🗌 No
l,			hereby attest th	nat I have perform	ed all necessary
,	g to ensure that this	member does not ha		_	=
initiati	ing growth hormone	therapy.			
Presci	riber Signature:				
11030	inder Orginatare:				
Please	e complete the followin	g:			
	Current:	height:	(inches)	weight:	(lbs)
	3 months prior:	height:	(inches)	weight:	(lbs)
	6 months prior	hoight:	(inches)	woight	(lba)
	6 months prior:	neight.	(inches)	weight:	(IDS)
COMA	TROPIN ACENTS	Describe mineralism			
	TROPIN AGENTS - F				
Please	e select one of the following Member has previous	_	from pediatric growth	hormone therapy	
	Please select one of		р 9	,	
	Request is for	r a preferred agent			
	Request is fo	r a non-preferred age	ent with a product-spe	ecific indication:	

RXP0016 (4/23) 01.01.2025 Page 2

	List indication:_				
	Prescriber would medical justification		on-preferred agent ove	er preferred agen	nt based on the following
Please	select one of the Request is for a	e following: preferred agent	normone deficiency and		owth hormone
	•		ent with a product-spec		
		d like to utilize a n	on-preferred agent ove		nt based on the following
☐ Membe therapy •	/ Member's curre Member has de	ent AIDS/HIV anti-	ed wasting or cachexia retroviral regimen: crease in total body we ed)		
			ey have performed all nitiating growth hormor		g to ensure there are no
testing to ens	ure that this me		hereby attest th ave expanding intrac		med all necessary r tumors prior to
Prescriber Sig	nature:				
Please comple	te the following:				
Curre	nt:	height:	(inches)	weight:	(lbs)
3 mon	ths prior:	height:	(inches)	weight:	(lbs)
	ths prior:		(inches)		, ,
	'	<u> </u>		<u> </u>	
<u> </u>	<u> </u>	– Initial Authoriz			
*The following	g documentation		☐ Yes ☐ No ☐ for diagnosis of "ad ☐ testing supporting the	_	none deficiency"
Member is 18 y	years of age or o	lder 🗆 Yes 🗆 N	No		
☐ Tria	one of the following and failure of O	NE preferred som	natropin products		

☐ Prescriber would like to utilize a Sogroya (somapacitan) over ALL preferred somatropin agents
based on the following medical justification:
Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial
lesions or tumors prior to initiating growth hormone therapy $\ \square$ Yes $\ \square$ No
I,hereby attest that I have performed all necessary
testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.
initiating growth normone therapy.
Prescriber Signature:
SOGROYA (SOMAPACITAN) – Reauthorization
Prescriber attests that they are continuing to monitor the member for intracranial tumor recurrence, progression
of underlying disease, or malignant transformation of skin lesions, if appropriate $\ \square$ Yes $\ \square$ No
I,hereby attest that I have performed all necessary
testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.
testing to ensure that this member does not have expanding intracranial lesions or tumors prior to

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

RXP0016 (4/23) 01.01.2025 Page 4